US equities
|
MU
$977.80
▲+5.28%
META
$612.46
▼-1.25%
NVDA
$215.66
▼-1.04%
TSLA
$402.50
▼-1.22%
SPCX
$144.52
▼-2.73%
SNDK
$1,392.85
▲+6.74%
GOOGL
$325.14
▲+1.42%
ORCL
$146.37
▲+12.14%
MU
$977.80
▲+5.28%
META
$612.46
▼-1.25%
NVDA
$215.66
▼-1.04%
TSLA
$402.50
▼-1.22%
SPCX
$144.52
▼-2.73%
SNDK
$1,392.85
▲+6.74%
GOOGL
$325.14
▲+1.42%
ORCL
$146.37
▲+12.14%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Latest News about Fragile X Syndrome
Recent news which mentions Fragile X Syndrome
Psychedelics And The Spectrum: Groundbreaking Study Details How One Firm Approaches Autism
April 20, 2023
Tickers
NMLSF
Tags
Penny Stocks
Top Stories
Contracts
From
Benzinga
Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder
February 14, 2023
Tickers
KONEF
NMLSF
Tags
Management
Legal
Health Canada Approval
From
Benzinga
First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval
December 27, 2022
Tickers
KONEF
NMLSF
Tags
Market News
psilocybin therapy
Cannabis
From
Benzinga